Patent · US Active

Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine

US11103570B2 · kind B2 · utility

0Cited by

2References

10Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Robin Steigerwald · Munich, DE
Markus Kalla · Penzberg, DE

Key dates

Filing date	Jun 15, 2016
Grant date	Aug 31, 2021
Priority date	—
Expiry date	Jun 15, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/32134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.